Mosaic ImmunoEngineering Inc. (CPMV) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Huntington Beach, CA, 미국. 현재 CEO는 Steven W. King.
CPMV 을(를) 보유 IPO 날짜 2013-01-02, 2 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $5.03M.
Mosaic ImmunoEngineering Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. It offers MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in mice, dogs, and humans. The company was founded in 2020 and is based in Novato, California.
